ReviewFrontiers in oncology2025
Transcatheter arterial chemoembolization for lung malignant tumors.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07738367 (A Single-Arm Phase II Study of Bronchial Artery Chemoembolization), which is not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single-Arm Phase II Study of Bronchial Artery Chemoembolization (BACE) Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Without Standard Treatment Options
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Safety and efficacy of drug-eluting beads versus conventional bronchial arterial chemoembolization for lung cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Recent advances in interstitial fluid dynamics for diagnostic, targeted drug delivery and precision medicine applications.Drug delivery and translational research · 2026Review
- Hydrogel-based tumor embolization and synergistic therapeutic strategies.Bioactive materials · 2026Review
- Impact of tumor mutation burden on the prognosis of patients with unresectable hepatocellular carcinoma undergoing transcatheter arterial chemoembolization combined with immunotherapy and anti-angiogenic drugs.Journal of gastrointestinal oncology · 2026Article
- Advances in Percutaneous and Endovascular Locoregional Therapies for Primary and Metastatic Lung Cancer.Cancers · 2026Review
- Radiotherapy combined with DEB-BACE for locally advanced lung cancer with obstructive atelectasis following first-line treatment failure: case report.Frontiers in medicine · 2026Article
- Article
- Case Report: Radiotherapy combined with DEB-TACE for hemorrhagic locally advanced solid tumors: a report of 3 cases.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcatheter arterial chemoembolization may enhance the local concentration and cytotoxicity of chemotherapeutic drugs and block the blood supply to the tumor, with an expectation to control the tumor, relieve hemoptysis, and prolong survival. This review will introduce the research progression of blood supply to lung cancer, discuss pulmonary artery chemoembolization (PACE) and bronchial artery chemoembolization (BACE) for lung cancer, including their indications and contraindications, operation techniques, efficacy assessments, combined treatments as well as their operating complications and the methods to prevent the adverse event. We will discuss the problems and challenges of percutaneous vascular intervention for lung cancer, such as the uncertainty of blood supply artery for lung cancer, the necessity of high-quality controlled studies, and the best choice for the indications. We hope to explore the direction of transcatheter arterial chemoembolization for lung cancer. The aim of this review is to provide a reference for the practice of chemoembolization by vascular interventional radiology for lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.